Abstract
Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.
Funding Information
  • National Natural Science Foundation of China (No.81770190, No. 81970161)
  • National Key Research and Development Programme of China (No. 2017YFA105500, 2017YFA105504)
  • Natural Science Foundation of Guangdong Province (No. 2019A1515011924)
  • Project of the Zhujiang Science & Technology Star of Guangzhou City (No.201806010029)

This publication has 61 references indexed in Scilit: